CN116509905A - Bifidobacterium bifidum biological preparation with constipation relieving effect - Google Patents
Bifidobacterium bifidum biological preparation with constipation relieving effect Download PDFInfo
- Publication number
- CN116509905A CN116509905A CN202310710709.XA CN202310710709A CN116509905A CN 116509905 A CN116509905 A CN 116509905A CN 202310710709 A CN202310710709 A CN 202310710709A CN 116509905 A CN116509905 A CN 116509905A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium bifidum
- parts
- preparation
- fermentation
- relieving effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 241000186016 Bifidobacterium bifidum Species 0.000 title claims abstract description 44
- 229940002008 bifidobacterium bifidum Drugs 0.000 title claims abstract description 44
- 206010010774 Constipation Diseases 0.000 title claims abstract description 40
- 230000000694 effects Effects 0.000 title claims abstract description 38
- 229920001202 Inulin Polymers 0.000 claims abstract description 9
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 9
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 9
- 229940029339 inulin Drugs 0.000 claims abstract description 9
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 9
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims abstract description 9
- 239000000832 lactitol Substances 0.000 claims abstract description 9
- 229960003451 lactitol Drugs 0.000 claims abstract description 9
- 235000010448 lactitol Nutrition 0.000 claims abstract description 9
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 9
- 239000003124 biologic agent Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 229920002472 Starch Polymers 0.000 claims abstract description 5
- 235000018927 edible plant Nutrition 0.000 claims abstract description 5
- 239000008107 starch Substances 0.000 claims abstract description 5
- 235000019698 starch Nutrition 0.000 claims abstract description 5
- 239000000945 filler Substances 0.000 claims abstract description 4
- 239000000796 flavoring agent Substances 0.000 claims abstract description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 4
- 239000000080 wetting agent Substances 0.000 claims abstract description 4
- 238000000855 fermentation Methods 0.000 claims description 40
- 230000004151 fermentation Effects 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 20
- 230000003213 activating effect Effects 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 11
- 230000004913 activation Effects 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 239000002609 medium Substances 0.000 claims description 10
- 239000002054 inoculum Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 239000003223 protective agent Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229940041514 candida albicans extract Drugs 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 239000012138 yeast extract Substances 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 244000309466 calf Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000001276 controlling effect Effects 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 229960001305 cysteine hydrochloride Drugs 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000011020 pilot scale process Methods 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000012137 tryptone Substances 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000013872 defecation Effects 0.000 abstract description 9
- 230000000968 intestinal effect Effects 0.000 abstract description 8
- 230000008855 peristalsis Effects 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 3
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 230000002550 fecal effect Effects 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a bifidobacterium bifidum biological agent with constipation relieving effect, and relates to the technical field of microbial agents; in order to provide a single-fungus biological agent which has no side effect and has constipation relieving effect; the concrete composition comprises the following components in parts by weight: 8-20 parts of carrier, 0.5-1.5 parts of bifidobacterium bifidum, 2-5 parts of isomaltooligosaccharide, 1-2 parts of lactitol, 0.8-2 parts of inulin and 0.1-0.3 part of stachyose, wherein the carrier is one or more than two of edible plant starch, medical filler, medical wetting agent and flavoring agent; the preparation method of the preparation comprises the following steps: the carrier, the isomaltooligosaccharide, the lactitol, the inulin and the stachyose are mixed according to the weight components and then dehumidified to obtain the mixture. The invention has no toxic or side effect, can increase defecation frequency, improve intestinal mucosa, can increase the water content of the excrement, has better effect on intestinal peristalsis, and thus has the effect of relieving constipation.
Description
Technical Field
The invention relates to the technical field of microbial preparations, in particular to a bifidobacterium bifidum biological preparation with a constipation relieving effect.
Background
With the development of socioeconomic performance and the change of dietary structure of people, constipation is receiving increasing attention as a disease that seriously affects the quality of life. Constipation is mainly characterized by slower transmission of intestinal contents, increased absorption of water in feces, further resulting in reduced defecation times and frequency, and accompanied by symptoms of abdominal distension and dry feces, and for patients with long-term constipation, severe patients are often accompanied by insomnia, anxiety, depression and irritability; secondly, a large number of metabolites in the intestinal tract can affect the development of the intestinal tract and even the brain function, and can have adverse effects on the whole heart and brain system.
At present, the common clinical treatment method of constipation is taking laxatives and prokinetic drugs, but the laxatives often cause dependence, aggravate constipation after stopping taking, and even have side effects such as nausea, abdominal pain, diarrhea and the like. Probiotics such as bifidobacterium bifidum are widely accepted at present as a treatment means with small side effects and obvious relieving effect. However, in the prior art, mixed bacteria or bacteria and traditional Chinese medicines or prebiotics are often used for preventing and relieving constipation, and researches on relieving constipation by using single bacteria are less, so that a bifidobacterium bifidum biological preparation without side effects and with a constipation relieving effect is provided.
Disclosure of Invention
The invention aims to solve the defects in the prior art, and provides a bifidobacterium bifidum biological agent with the effect of relieving constipation.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
a bifidobacterium bifidum biological agent with constipation relieving effect comprises the following components in parts by weight: 8-20 parts of carrier, 0.5-1.5 parts of bifidobacterium bifidum, 2-5 parts of isomaltooligosaccharide, 1-2 parts of lactitol, 0.8-2 parts of inulin and 0.1-0.3 part of stachyose, wherein the carrier is one or more than two of edible plant starch, medical filler, medical wetting agent and flavoring agent;
the preparation method of the preparation comprises the following steps: mixing the carrier, the isomaltooligosaccharide, the lactitol, the inulin and the stachyose according to the weight components, then dehumidifying to obtain a mixture, uniformly mixing the mixture with the bifidobacterium bifidum, and packaging.
Preferably: the method for culturing bifidobacterium bifidum comprises the following steps:
a1: preparing a material;
a2: activating strains: activating and preserving strains by an activating culture medium, carrying out anaerobic culture at 37 ℃ for 60-72 hours to obtain single colonies, inoculating according to the inoculum size of 5% by volume, activating for 2-4 generations before the strains are used, and controlling the activating culture within 48 hours;
a3: culturing strains: inoculating the activated strain into a culture medium filled with 2000mL of seeds according to the inoculum size of 5% by volume, and then placing the culture medium in an incubator, (37+/-1) DEG C anaerobic culture for 12-36 hours;
a4: obtaining fermentation liquor;
a5: cooling the fermentation broth to 2-15deg.C, centrifuging at 6500r/min and 4deg.C for 8-15min, removing supernatant, emulsifying and drying.
Preferably: the material comprises a strain, an activation medium, a fermentation medium and a protective agent;
the strain is bifidobacterium bifidum BB-G90;
the preparation raw materials of the activation culture medium comprise the following components in parts by weight: 1 part of tryptone, 0.4 part of calf extract powder, 0.3 part of yeast extract, 0.3 part of lactose, 0.4 part of NaCl and 0.1 part of cysteine hydrochloride;
the preparation of the fermentation medium comprises the following raw materials in parts by weight: glucose 12 g.L -1 Lactose 24 g.L -1 Peptone 12 g.L -1 24 g.L yeast extract -1 Tween 80 g.L -1 ；
The preparation of the protective agent comprises the following raw materials in parts by weight: skim milk powder 0.12 g.L -1 Trehalose 0.16g·L -1 0.001 g.L of alcohols or salts -1 。
Preferably: the method for obtaining the fermentation broth comprises the following steps:
b1: preparing a fermentation medium, regulating the pH value to 6.8+/-0.1, and sterilizing for 15min at 121 ℃;
b2: inoculating the cultured seed liquid into a small-sized fermentation tank according to the inoculum size of 2-5% of the volume ratio after sterilization, and performing primary fermentation in the small-sized fermentation tank under the condition of pH of 5.0+0.5;
b3: transferring to a large-scale fermentation tank for pilot scale test, and fermenting for 16-22 h.
Preferably: the fermentation conditions of the fermentation liquid are as follows: culturing at 37+/-1 deg.c and tank pressure of 0.02-0.05 MPa;
the OD600nm value of the fermentation broth is 5.62-15.
Preferably: the emulsifying operation method is that bacterial mud and a protective agent are mixed according to the mass ratio of 1:2.
Preferably: the drying is a vacuum freeze drying process, and after pre-freezing for 3 hours at the temperature of minus 50 ℃, the freeze drying is carried out under the vacuum degree of 0.1 Pa.
Preferably: the viable count of the bifidobacterium bifidum adopts a plate mixed bacteria anaerobic culture counting method, and the viable count is more than or equal to 5.0x10 9 CFU/g；
The plate mixed bacteria anaerobic culture counting method specifically comprises the following steps:
c1: weighing 0.5mL of the sample, and dissolving the sample in 4.5mL of sterilized physiological saline;
c2: adopting 10-time gradient dilution to sample liquid, and selecting a pouring plate with proper dilution to uniformly distribute the sample liquid in an activation culture medium;
and C3: anaerobic culture was performed for 48 hours at 37.+ -. 1 ℃ and the colony numbers were counted.
Preferably: the type of the preparation comprises one of powder, granule, capsule, tablet or pill.
The beneficial effects of the invention are as follows:
1. according to the invention, the bifidobacterium bifidum is mixed with the carrier and dried, so that the bifidobacterium bifidum biological preparation is obtained, has no toxic or side effect, can increase defecation frequency, improve intestinal mucosa, can increase the water content of the feces, has a better effect on intestinal peristalsis, and thus has the effect of relieving constipation.
2. The preparation provided by the invention can reduce the abnormally-increased short-chain fatty acid level in the intestinal tract, lighten colorectal inflammation, further can help reduce colon pathological damage from the side, is simple to prepare, has stable effect and is easy for industrialized production.
3. The preparation of the invention can replace medicines to treat constipation, can also be used as an auxiliary means for clinically treating colorectal cancer, or can be applied to medicines or some fermented foods and functional foods, thereby widely playing the roles and being widely applied.
4. The bifidobacterium bifidum can be metabolized to produce organic acid after intestinal tract colonization, can reduce the pH value in intestinal cavities, and can directly or indirectly act on large intestine and other organs by influencing intestinal flora, adjusting intestinal permeability and immunological parameters and producing regulatory or bioactive metabolites, thereby achieving the effect of relieving constipation.
Drawings
FIG. 1 is a schematic diagram of a preparation flow of bifidobacterium bifidum;
fig. 2 is a schematic diagram of a preparation process of a bifidobacterium bifidum biological agent with constipation relieving effect.
Detailed Description
The technical scheme of the patent is further described in detail below with reference to the specific embodiments.
Embodiments of the present patent are described in detail below, examples of which are illustrated in the accompanying drawings, wherein the same or similar reference numerals refer to the same or similar elements or elements having the same or similar functions throughout. The embodiments described below by referring to the drawings are exemplary only for explaining the present patent and are not to be construed as limiting the present patent.
Example 1:
a bifidobacterium bifidum biological agent with constipation relieving effect, as shown in figure 1, comprises the following components in parts by weight: 18 parts of carrier, 0.9 part of bifidobacterium bifidum, 4 parts of isomaltooligosaccharide, 1 part of lactitol, 1 part of inulin and 0.1 part of stachyose.
The carrier is one of edible plant starch, medical filler, medical wetting agent, flavoring agent and the like, and the edible plant starch is preferable in the embodiment.
The method for culturing bifidobacterium bifidum comprises the following steps:
a1: preparing a material;
a2: activating strains: activating and preserving strains by an activating culture medium, carrying out anaerobic culture at 37 ℃ for 60-72 hours to obtain single colonies, inoculating according to the inoculum size of 5% by volume, activating for 2-4 generations before the strains are used, and controlling the activating culture within 48 hours;
a3: culturing strains: inoculating the strain after the final generation activation into a culture medium filled with 2000mL of seeds according to the inoculum size of 5% by volume ratio, and then placing the strain in an incubator for anaerobic culture for 12-36h at the temperature of (37+/-1);
a4: obtaining fermentation liquor;
a5: cooling the fermentation broth to 2-15deg.C, centrifuging at 6500r/min and 4deg.C for 8-15min, removing supernatant, emulsifying and drying.
Further, the materials include bacterial species, activation media, fermentation media, and protectants.
Preferably, the strain is bifidobacterium bifidum BB-G90, provided by the collection of strains from the division of the wetting bioengineering (Shanghai) company.
Preferably, the preparation raw materials of the activation culture medium comprise the following components in parts by weight: 1 part of tryptone, 0.4 part of calf extract powder, 0.3 part of yeast extract, 0.3 part of lactose, 0.4 part of NaCl and 0.1 part of cysteine hydrochloride.
Preferably, the preparation of the fermentation medium comprises the following raw materials in parts by weight: glucose 12 g.L -1 Lactose 24 g.L -1 Peptone 12 g.L -1 24 g.L yeast extract -1 Tween 80 g.L -1 。
Preferably, the preparation of the protective agent comprises the following raw materials in parts by weight: skim milk powder 0.12 g.L -1 Trehalose 0.16 g.L -1 0.001 g.L of alcohols or salts -1 。
Further, the method for obtaining the fermentation broth comprises the following steps:
b1: preparing a fermentation medium, regulating the pH value to 6.8+/-0.1, and sterilizing for 15min at 121 ℃;
b2: inoculating the cultured seed liquid into a small-sized fermentation tank according to the inoculum size of 2-5% of the volume ratio after sterilization, and performing primary fermentation in the small-sized fermentation tank under the condition of pH of 5.0+0.5;
b3: transferring to a large-scale fermentation tank for pilot scale test, and fermenting for 16-22 h.
Preferably, the OD600nm value of the fermentation broth is 5.62-15, and the viable count of the fermentation broth in the embodiment is 1.80×10 9 CFU/mL。
Preferably, the fermentation conditions of the fermentation broth are: the culture temperature is 37+/-1 ℃, the tank pressure is 0.02-0.05 MPa, and the nitrogen is 0.4m 3 /h。
Further, the emulsification method comprises bacterial sludge and a protective agent in a mass ratio of 1:2.
Preferably, the drying is vacuum freeze drying process, pre-freezing at-50deg.C for 3 hr, and lyophilizing at-50deg.C and vacuum degree of 0.1Pa to obtain dried fungus powder with viable count of more than or equal to 2.0X10 11 CFU/g。
Further, the method for measuring the viable count adopts a plate mixed bacteria anaerobic culture counting method;
preferably, the plate mixed bacteria anaerobic culture counting method specifically comprises the following steps:
c1: weighing 0.5mL of the sample (namely the bacterial powder) and dissolving the sample in 4.5mL of sterilized physiological saline;
c2: adopting 10-time gradient dilution to sample liquid, and selecting a pouring plate with proper dilution to uniformly distribute the sample liquid in an activation culture medium;
and C3: anaerobic culture was performed for 48 hours at 37.+ -. 1 ℃ and the colony numbers were counted.
The type of the preparation comprises one of powder, granules, capsules, tablets or pills and the like.
When the preparation is used, the preparation which can reduce colon pathological damage and has the function of relieving constipation is provided, the defecation frequency is increased, and the intestinal mucosa is improved;
relieving constipation, increasing water content of feces, and promoting intestinal peristalsis;
is applied to improving intestinal flora, reducing abnormally elevated short chain fatty acid levels in the intestinal tract, and relieving colorectal inflammation, thereby inhibiting colorectal cancer;
after taking the product for one week, the fecal moisture content is increased by 15-40% compared with that before taking the product, and the fecal moisture content (%) = (fecal wet weight-fecal dry weight)/fecal wet weight x100.
Example 2:
a bifidobacterium bifidum biological preparation with constipation relieving effect, as shown in figures 1-2, comprises the following components in parts by weight: 18 parts of carrier, 0.9 part of bifidobacterium bifidum, 4 parts of isomaltooligosaccharide, 1 part of lactitol, 1 part of inulin and 0.1 part of stachyose.
The preparation method of the preparation comprises the following steps: and uniformly mixing the carrier, the isomaltooligosaccharide, the lactitol, the inulin and the stachyose according to the weight components, drying to obtain a mixture, uniformly mixing the mixture with bifidobacterium bifidum, and packaging.
The viable count of bifidobacterium bifidum in the preparation is more than or equal to 5.0X10 9 CFU/g。
When the embodiment is used, the preparation is simple, the effect is stable, the cost is low, and the industrialized production is easy.
The bifidobacterium bifidum can obviously improve the content of MTL in serum and the content of 5-HT in colon tissues, thereby having obvious influence on the contraction of stomach, the secretion of gastric juice and the contraction of intestinal muscle, improving the small intestine propulsion rate, having better effect on intestinal peristalsis and effectively relieving constipation.
After taking the product for one week, the fecal moisture content is increased by 10-25% compared with that before taking the product, and the fecal moisture content (%) = (fecal wet weight-fecal dry weight)/fecal wet weight x100.
Application example 1:
observe samples (no person exiting halfway): 120 test people with 30+ years old and constipation symptom of at least two months are selected, 60 men and women are divided into 2 groups, one group is an experimental group and the other group is a control group, and each group is 30-50 years old, 30 people 51 years old and 30 people above.
Constipation symptoms: the defecation is laborious, the defecation is dry ball-shaped or hard, the defecation has an endless feeling, the anus and rectum have a blocking feeling when the defecation is performed, and the defecation times are less than twice per week.
The testing method comprises the following steps: under the condition of keeping the original life, the testers of the experimental group take the bifidobacterium bifidum biological preparation prepared in the examples 1-2 according to the frequency of twice 1 day; the control group took commercial probiotic preparation.
Constipation improvement results are shown in the following table:
as can be seen from the above table, the experimental group taking the bifidobacterium bifidum biological agent in the application has more obvious constipation improving effect than the control group, wherein the 30-50 year old group has more rapid constipation improving effect, and the 51 year old and 51 year old group has relatively prolonged constipation improving effect.
The foregoing is only a preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art, who is within the scope of the present invention, should make equivalent substitutions or modifications according to the technical scheme of the present invention and the inventive concept thereof, and should be covered by the scope of the present invention.
Claims (9)
1. A bifidobacterium bifidum biological agent with constipation relieving effect comprises the following components in parts by weight: 8-20 parts of carrier, 0.5-1.5 parts of bifidobacterium bifidum, 2-5 parts of isomaltooligosaccharide, 1-2 parts of lactitol, 0.8-2 parts of inulin and 0.1-0.3 part of stachyose, and is characterized in that the carrier is one or more than two of edible plant starch, medical filler, medical wetting agent and flavoring agent;
the preparation method of the preparation comprises the following steps: mixing the carrier, the isomaltooligosaccharide, the lactitol, the inulin and the stachyose according to the weight components, then dehumidifying to obtain a mixture, uniformly mixing the mixture with the bifidobacterium bifidum, and packaging.
2. The bifidobacterium bifidum biological preparation with constipation relieving effect according to claim 1, wherein the method for culturing bifidobacterium bifidum comprises the following steps:
a1: preparing a material;
a2: activating strains: activating and preserving strains by an activating culture medium, carrying out anaerobic culture at 37 ℃ for 60-72 hours to obtain single colonies, inoculating according to the inoculum size of 5% by volume, activating for 2-4 generations before the strains are used, and controlling the activating culture within 48 hours;
a3: culturing strains: inoculating the activated strain into a culture medium filled with 2000mL of seeds according to the inoculum size of 5% by volume, and then placing the culture medium in an incubator for anaerobic culture for 12-36h at 37+/-1 ℃;
a4: obtaining fermentation liquor;
a5: cooling the fermentation broth to 2-15deg.C, centrifuging at 6500r/min and 4deg.C for 8-15min, removing supernatant, emulsifying and drying.
3. The bifidobacterium bifidum biological preparation with constipation relieving effect according to claim 2, wherein the material comprises a strain, an activation medium, a fermentation medium and a protective agent;
the strain is bifidobacterium bifidum BB-G90;
the preparation raw materials of the activation culture medium comprise the following components in parts by weight: 1 part of tryptone, 0.4 part of calf extract powder, 0.3 part of yeast extract, 0.3 part of lactose, 0.4 part of NaCl and 0.1 part of cysteine hydrochloride;
the preparation of the fermentation medium comprises the following raw materials in parts by weight: glucose 12 g.L -1 Lactose 24 g.L -1 Peptone 12 g.L -1 24 g.L yeast extract -1 Tween 80 g.L -1 ；
The preparation of the protective agent comprises the following raw materials in parts by weight: skim milk powder 0.12 g.L -1 Trehalose 0.16 g.L -1 Alcohols or salts 0.001g·L -1 。
4. The bifidobacterium bifidum biological preparation with constipation relieving effect according to claim 2, wherein the method for obtaining the fermentation broth comprises the following steps:
b1: preparing a fermentation medium, regulating the pH value to 6.8+/-0.1, and sterilizing for 15min at 121 ℃;
b2: inoculating the cultured seed liquid into a small-sized fermentation tank according to the inoculum size of 2-5% of the volume ratio after sterilization, and performing primary fermentation in the small-sized fermentation tank under the condition of pH of 5.0+0.5;
b3: transferring to a large-scale fermentation tank for pilot scale test, and fermenting for 16-22 h.
5. The bifidobacterium bifidum biological preparation with constipation relieving effect according to claim 4, wherein the fermentation conditions of the fermentation broth are: the culture temperature is 37+/-1 ℃, and the tank pressure is 0.02-0.05 MPa;
the OD600nm value of the fermentation broth is 5.62-15.
6. The biological preparation of bifidobacterium bifidum with constipation relieving effect according to claim 3, wherein the emulsifying operation method is bacterial mud and protective agent in a mass ratio of 1:2.
7. The bifidobacterium bifidum biological preparation with constipation relieving effect according to claim 6, wherein the drying is a vacuum freeze-drying process, and the freeze-drying is carried out at a temperature of-50 ℃ and a vacuum degree of 0.1Pa after pre-freezing for 3 hours at-50 ℃.
8. The biological preparation of bifidobacterium bifidum with constipation relieving effect according to claim 1, wherein the viable count of bifidobacterium bifidum is greater than or equal to 5.0x10 by adopting a plate mixed anaerobic culture counting method 9 CFU/g；
The plate mixed bacteria anaerobic culture counting method specifically comprises the following steps:
c1: weighing 0.5mL of the sample, and dissolving the sample in 4.5mL of sterilized physiological saline;
c2: adopting 10-time gradient dilution to sample liquid, and selecting a pouring plate with proper dilution to uniformly distribute the sample liquid in an activation culture medium;
and C3: anaerobic culture was performed at 37.+ -. 1 ℃ for 48 hours, and the colony numbers were counted.
9. The bifidobacterium bifidum biological preparation with constipation relieving effect as claimed in claim 8, wherein the type of preparation comprises one of powder, granule, capsule, tablet or pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310710709.XA CN116509905A (en) | 2023-06-15 | 2023-06-15 | Bifidobacterium bifidum biological preparation with constipation relieving effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310710709.XA CN116509905A (en) | 2023-06-15 | 2023-06-15 | Bifidobacterium bifidum biological preparation with constipation relieving effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116509905A true CN116509905A (en) | 2023-08-01 |
Family
ID=87406583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310710709.XA Pending CN116509905A (en) | 2023-06-15 | 2023-06-15 | Bifidobacterium bifidum biological preparation with constipation relieving effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116509905A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117085042A (en) * | 2023-10-20 | 2023-11-21 | 潍坊君薇生物科技有限责任公司 | Bifidobacterium bifidum BL002 metagen and application thereof |
-
2023
- 2023-06-15 CN CN202310710709.XA patent/CN116509905A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117085042A (en) * | 2023-10-20 | 2023-11-21 | 潍坊君薇生物科技有限责任公司 | Bifidobacterium bifidum BL002 metagen and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106834187B (en) | Bifidobacterium bifidum and application thereof | |
| CN110106122B (en) | Lactobacillus plantarum capable of improving sleep and application thereof | |
| CN107893044A (en) | One plant of bifidobacterium longum and its application | |
| CN114703102B (en) | Bifidobacterium bifidum for relieving constipation and application thereof | |
| TW202200029A (en) | Composition for promoting defecation and use therefor | |
| CN109609420B (en) | Helicobacter pylori-resistant probiotic composition and preparation method thereof | |
| CN116731891B (en) | Bifidobacterium breve B2798 and application thereof in preparation of probiotic preparation | |
| CN116286551B (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
| CN116121154B (en) | Leuconostoc lactis and application thereof | |
| CN114774313A (en) | Application of lactobacillus rhamnosus LRa05 in preparing product for relieving constipation or regulating intestinal flora | |
| CN116509905A (en) | Bifidobacterium bifidum biological preparation with constipation relieving effect | |
| CN107692219A (en) | A kind of hypoglycemic fruit zymotic fluid and preparation method thereof | |
| CN107227275A (en) | A kind of lactobacillus fermenti HY01 and application thereof | |
| CN117343857A (en) | Probiotic combination and application thereof in intestinal tract regulation, private care and mastitis prevention | |
| CN109331045A (en) | It is a kind of containing Bee Pollen, the probiotic composition of active carbon and preparation method thereof | |
| CN116574648A (en) | Lactobacillus plantarum and application thereof in relieving constipation | |
| CN116676210A (en) | Bifidobacterium animalis subspecies lactis for improving functional constipation and application thereof | |
| CN113969253B (en) | Bifidobacterium lactis JYBR-390 with constipation treatment effect and application and product thereof | |
| CN116855413B (en) | Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof | |
| CN115895966B (en) | Bifidobacterium bifidum BL002 for assisting in relieving gout and application thereof | |
| CN112210511A (en) | Bifidobacterium longum with functions of inhibiting HT-29 cell proliferation and benefiting life and application thereof | |
| CN111345473A (en) | Probiotics composition containing yolk antibody IgY and application preparation | |
| CN115844019A (en) | Probiotic capable of regulating intestinal tract and application | |
| CN109897795A (en) | A kind of microbial bacterial agent and its application on anti-treat constipation | |
| CN115251395A (en) | Compound probiotic formula for relieving constipation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |